CAAS Capital Management’s Solid Biosciences SLDB Stock Holding History

CAAS Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-64,112	Closed	-$162K	–	693
2023 Q3	$162K	Sell	64,112 -37,569	-37%	-$146K	0.01%	526
2023 Q2	$533K	Sell	101,681 -142,837	-58%	-$804K	0.04%	374
2023 Q1	$1.16M	Sell	244,518 -39,169	-14%	-$235K	0.06%	267
2022 Q4	$4.81M	Buy	+283,687	New	+$1.86M	0.29%	100
2021 Q2	–	Sell	-2,866	Closed	-$238K	–	1255
2021 Q1	$238K	Buy	+2,866	New	+$317K	﹤0.01%	1030

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's SLDB Position: Q4 2023 in Review

CAAS Capital Management sold out of Solid Biosciences (SLDB) in Q4 2023, closing a stake of 64,112 shares — an estimated $162K sold.

CAAS Capital Management first reported a position in SLDB in Q1 2021 and held it in 5 quarters. The position peaked at $4.81M in Q4 2022. 39 funds tracked by Wall St. Rank hold SLDB as of Q4 2023.

CAAS Capital Management reported no remaining Solid Biosciences position as of Q4 2023 after selling out during the quarter.
CAAS Capital Management sold 64,112 Solid Biosciences shares in Q4 2023, an estimated $162K.
CAAS Capital Management first reported a position in Solid Biosciences in Q1 2021 and held it in 5 quarters.
CAAS Capital Management's Solid Biosciences position peaked at $4.81M in Q4 2022.
39 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2023.

Based on CAAS Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.